Developing Novel Drug Formulations for the Treatment of Chronic Pain and Addiction; Report Available here: www.lifescicapital.com/equity-research/biodelivery-sciences/
NEW YORK, NY / ACCESSWIRE / September 24, 2015 / LifeSci Capital, LLC, a research-driven investment bank with deep domain expertise in the life sciences sector, today announced that it has initiated coverage of BioDelivery Sciences (NasdaqCM: BDSI), a specialty pharmaceutical company developing novel treatments for the pain and opioid dependence markets using its proprietary BEMA buccal delivery platform. The Company has launched Bunavail to treat opioid dependence and is developing Belbuca in partnership with Endo Pharmaceuticals (NasdaqGS: ENDP) for chronic pain.
Bunavail is a buprenorphine and naloxone combination that may have several advantages over existing opioid dependence therapies, including more efficient delivery of buprenorphine, improved gastrointestinal tolerability, and greater ease of use. BioDelivery Sciences has made progress in promoting adoption of Bunavail through expanded access to managed care providers and Medicaid. Since its November launch, roughly 1,800 physicians have written over 36,000 Bunavail prescriptions.
Belbuca is a buprenorphine therapy for chronic pain patients that BioDelivery Sciences is developing in partnership with Endo. There is a large market opportunity for buprenorphine-based pain management due to the recent rescheduling of hydrocodone as a Schedule II controlled substance. The companies submitted an NDA for Belbuca in December 2014 and have a PDUFA action date of October 23, 2015. If approved, BDSI is entitled to a $50 million milestone payment as part of the partnership agreement.
In a 37 page Initiation Report, LifeSci Capital explains the commercial strategy for Bunavail in treating opioid dependence and the potential market opportunity for buprenorphine therapies in the chronic pain market.
Dr. Isaacson's full Initiation Report, including important disclosures, is available to download at no cost at the LifeSci Capital website, www.lifescicapital.com/equity-research/. In addition to this Initiation Report, LifeSci Capital intends to provide ongoing coverage and event-based research updates on BioDelivery Sciences as developments occur.
The LifeSci Capital research team is led by Dr. Jerry Isaacson, an industry veteran with broad experience in biotechnology, having worked in both public and private biotech companies in areas ranging from medicinal chemistry and analytical chemistry to patents and investor/public relations. Dr. Isaacson holds a Bachelor of Arts degree in Chemistry from Harvard University and received his Ph.D. in Organic Chemistry from the University of California in San Diego.
About LifeSci Capital:
LifeSci Capital (Member: FINRA/SIPC) is a research-driven investment bank with deep domain expertise in the life sciences. Our service model as a boutique investment bank is unique in that we exclusively serve emerging life science companies that discover, develop, and commercialize innovative products. We view our clients as our partners, and we work closely with them to establish and execute their capital markets strategies. Our broadly-distributed equity research product is differentiated and provides a deep understanding of our clients' businesses and the opportunities they are addressing. To learn more about LifeSci Capital, visit the company's website, www.lifescicapital.com.
Analyst Contact:
Jerry Isaacson, Ph.D.
Phone: (646) 597-6991
Email: jisaacson@lifescicapital.com
SOURCE: LifeSci Capital, LLC